Journal of Virus Eradication 2016; 2 (Supplement 4): 1–6
Review
Revised working paper following AVAREF meeting February 2019.
WHO has published a roadmap aiming to coordinate partners’ actions and contributions to the licensing and roll-out of Merck’s Ebola vaccine (VSV-ZEBOV) in African countries. The vaccine was developed during the West Africa Ebola epi...demic of 2014-2016, during which more than 11 000 people lost their lives to the disease. The vaccine was tested in European and African countries at the time and is currently used under an “expanded access” protocol in the Democratic Republic of Congo.
WHO will expedite prequalification and licensing of the vaccine for use in countries at risk of Ebola outbreaks and will coordinate work between those countries’ regulatory authorities and the European Medicines Agency and the US Food and Drug Administration.
more
Nepal is on target to meet the Millennium Development Goals for maternal and child health despite high levels of poverty, poor infrastructure, difficult terrain and recent conflict. Each year, nearly 35000 Nepali children die before their fifth birthday, with almost two-thirds of these deaths occurr...ing in the first month of life, the neonatal period. As part of a multi-country analysis, we examined changes for newborn survival between 2000 and 2010 in terms of mortality, coverage and health system indicators as well as national and donor funding.
more
Of the 50 antibiotics in the pipeline, 32 target WHO priority pathogens but the majority have only limited benefits when compared to existing antibiotics. Two of these are active against the multi-drug resistant Gram-negative bacteria, which are spreading rapidly and require urgent solutions.
Gr...am-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli, can cause severe and often deadly infections that pose a particular threat for people with weak or not yet fully developed immune systems, including newborns, ageing populations, people undergoing surgery and cancer treatment.
The report highlights a worrying gap in activity against the highly resistant NDM-1 (New Delhi metallo-beta-lactamase 1), with only three antibiotics in the pipeline. NDM-1 makes bacteria resistant to a broad range of antibiotics, including those from the carbapenem family, which today are the last line of defence against antibiotic-resistant bacterial infections.
more
The focus of the current quarterly edition of Eurohealth (from the European Observatory on Health Systems and Policies) is Antimicrobial Resistance (AMR) and contains the following articles:
• Strengthening implementation of AMR national action plans
• Fostering clinical developmen...t and commercialisation of novel antibiotics
• Tackling AMR in the community
• Quantifying the benefits of vaccines in combating AMR
more
Global procurement for COVID-19 vaccines
The two-year impact report for the Access to COVID-19 Tools (ACT) Accelerator details impact, case studies and timelines of key milestones for the Diagnostics, Therapeutics and Vaccines pillars, as well as the Health Systems and Response Connector.
In this document, recommendations are provided on designing and implementing
a cross-sectional serosurvey using school-based sampling to estimate age-specific
DENV seroprevalence to inform a country’s national dengue vaccination program.
The document includes recommendations for methods for ...planning and conducting
serosurveys, including survey design, specimen collection, laboratory testing, data
analysis, and the interpretation and reporting of results.
more
interim guidance, 27 May 2021
All countries should increase their level of preparedness, alert and response to identify, manage and care for new cases of COVID-19. Countries should prepare to respond to different public health scenarios, recognizing that there is no one-size-fits-all approach to ma...naging cases and outbreaks of COVID-19. Each country should assess its risk and rapidly implement the necessary measures at the appropriate scale to reduce both COVID-19 transmission and economic, public and social impacts.
more
This article is part four in a series of explainers on vaccine development and distribution
Available in different languages
This article is part two in a series of explainers on vaccine development and distribution. Part one focused on how vaccines work to protect our bodies from disease-carrying germs. This article focuses on the ingredients in a vaccine and the three clinical trial phases. Part three outlines the nex...t part of the vaccine journey: the steps from completing the clinical trial phases through to distribution
Available in English, French, Spanish, Arabic, Chinese and Russian
more
This article is part four in a series of explainers on vaccine development and distribution.
Part one focused on how vaccines work to protect our bodies from disease-carrying germs.
Part two focused on the ingredients in a vaccine and the three clinical trial phases.
Part three focused on the ste...ps from completing the clinical trial phases through to distribution.
This document outlines the different types of vaccines.
Available in English, French, Spanisch, Arabic, Chinese and Russian
more
14 July 2021 This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series.
COVID-19 vaccines have proven to be safe, ...effective and life-saving. Like all vaccines, they do not fully protect everyone who is vaccinated, and we do not yet know how well they can prevent people from transmitting the virus to others. So as well as getting vaccinated, we must also continue with other measures to fight the pandemic.
Available in English, French, Spanish, Arabic, Chinese and Russian
more
Noncommunicable diseases (NCDs) such as cancer, cardiovascular diseases, diabetes and chronic respiratory diseases and their risk factors are an increasing public health and development challenge in Kyrgyzstan. This report provides evidence through three analyses that NCDs reduce economic outp...ut and discusses potential options in response, outlining details of their relative returns on investment. An economic burden analysis shows that economic losses from NCDs are equivalent to 3.9% of gross domestic product. An intervention costing analysis provides an estimate of the funding required to implement a set of policy interventions for prevention and clinical interventions. A cost–benefit analysis compares these implementation costs with the estimated health gains and identifies which policy packages would give the greatest returns on investment.
more
29 April 2022
What are the new vaccines in the pipeline? What are the challenges to turning vaccines into vaccination ? What timelines can we expect for future vaccines? WHO’s Dr Katherine O’Brien explains in Science in 5.
mRNA technologies. What is their future and scope, and what are the challenges that countries might face in rolling them out? Hello and welcome to Science in5. I'm Vismita Gupta-Smith. We are talking to Dr.Soumya Swaminathan today. Soumya, talk to us about mRNA technologies. What is the future?